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he search  for  new  biomarkers  in systemic
clerosis
 busca  por  novos  biomarcadores  na  esclerose  sistêmicaystemic sclerosis (SSc) is a chronic autoimmune rheumatic
isease with a heterogeneous course, whose follow-up and
reatment remain challenging. In this context, the identiﬁca-
ion of biomarkers for assessing the disease activity, the risk
f involvement of internal organs, and of their prognosis is
xtremely important.
In recent years, there have been many  advances in the
dentiﬁcation of serum biomarkers and of certain pheno-
ypes associated with an increased risk of developing certain
anifestation such as interstitial lung disease, pulmonary
rterial hypertension, and renal scleroderma crisis.1 Thus,
he presence of anti-Scl70 antibodies is associated with the
iffuse cutaneous clinical form and with a worse progno-
is. Serum KL-6, surfactant D protein, lysyl oxidase (LOX),
enascin-C, CXCL4, and CCL18 seem to be promising biomark-
rs for assessing the severity of ﬁbrosis in interstitial lung
iseases associated with SSc.2,3 On the other hand, the levels
f natriuretic peptides BNP and NT-proBNP have been used
s pulmonary arterial hypertension biomarkers.1 A recent
tudy showed signiﬁcantly higher serum levels of placen-
al growth factor and soluble receptor 1 of VEGF in patients
ith pulmonary hypertension compared to SSc patients
ithout pulmonary hypertension, indicating their potential
s biomarkers for pulmonary hypertension.4 Despite these
dvances, further studies are required in order to identify and
alidate biomarkers for patients with SSc.
In this issue, four studies evaluating different clinical
nd laboratory characteristics of patients with SSc were
ublished.
Olewicz-Gawlik et al. evaluated the serum levels of Clara
ell protein (CC16) in patients with SSc.5 CC16 is a protein
xpressed in the respiratory tract, secreted by cells located in
he bronchial epithelium, which has anti-inﬂammatory and
nti-oxidant properties. Although no difference was found in
erum levels of CC16 between SSc patients and controls, anassociation between CC16 levels and a more  severe pulmonary
involvement was observed. The results corroborate the ﬁnd-
ings of a previous study, which found an association between
levels of CC16 and lung activity in scleroderma patients,6 and
suggest that CC16 may be a potential serum biomarker in the
evaluation of interstitial lung disease.
On the other hand, Sampaio-Barros et al. found a signiﬁ-
cant correlation between serum levels of 25-hydroxyvitamin
D (25OHD) and quality of life in patients with diffuse SSc.7
These authors also found a negative correlation between a
higher degree of devascularization in nail fold capillaroscopy
and levels of vitamin D, as well as reduced levels of vitamin
D in patients with anti-Scl70 antibody positivity. These results
suggest that serum levels of vitamin D can be used as biomark-
ers for worse quality of life. However, one cannot conclude that
the reduction in vitamin D levels would be directly related to a
poorer quality of life of these patients, or if such correlation is
related to a more  severe disease since the authors assessed
only patients with diffuse disease. On the other hand, the
ﬁndings are consistent with many  studies describing a high
frequency of 25OHD deﬁciency in patients with SSc. Addition-
ally, in vitro studies suggest that multiple endogenous forms
of vitamin D3 have antiﬁbrotic properties and may be a future
therapeutic target in SSc.8
Finally, two studies of the same group evaluated two
aspects that demonstrate the clinical heterogeneity of SSc.9,10
In the ﬁrst study, a high frequency of polyautoimmunity
and of familial autoimmunity in a group of 60 patients with
SSc was observed.9 The second study aimed to analyze the
characteristics of patients with and without arthritis or with
overlap syndrome with rheumatoid arthritis.10 The frequency
for arthritis was 26%, and that for overlap with rheuma-
toid arthritis was 6.6% – ﬁndings similar to previous studies.
Interestingly, patients with arthritis and overlap syndrome
showed a tendency to a poorer quality of life compared to
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patients without arthritis. There was also a high frequency
of radiographic changes characterized by joint space narrow-
ing and/or subchondral bone erosion, suggesting that, in these
patients, arthritis can develop more  aggressively.
In summary, the studies published reveal the multiple
facets of SSc and reinforce the need to ﬁnd reproducible, easily
applicable in clinical practice, biomarkers in order to iden-
tify patients at risk of developing more  serious manifestations
and, ﬁnally, for an early treatment.
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